Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Matthew P. Cheng; José L. Orejas; Esther Arbona-Haddad; Tyler D. Bold; Isaac H. Solomon; Kaiwen Chen; Alisha Pandit; Amanda E. Kusztos; Kaelyn C. Cummins; Alexis Liakos; Francisco M. Marty; Sophia Koo; Sarah P. Hammond

doi:10.1111/myc.13013

Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Matthew P. Cheng, José L. Orejas, Esther Arbona-Haddad, Tyler D. Bold, Isaac H. Solomon, Kaiwen Chen, Alisha Pandit, Amanda E. Kusztos, Kaelyn C. Cummins, Alexis Liakos, Francisco M. Marty, Sophia Koo, Sarah P. Hammond

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

Original language	English (US)
Pages (from-to)	58-64
Number of pages	7
Journal	Mycoses
Volume	63
Issue number	1
DOIs	https://doi.org/10.1111/myc.13013
State	Published - Jan 1 2020

Bibliographical note

Funding Information:
MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Santé Québec.

Funding Information:
These results were presented in abstract form at IDWeek 2018, Abstract #358. This manuscript was prepared as part of routine work. MPC, JLO, EAH, TDB, IHS, KCC, AP, AEK, KC and SK have no relevant disclosures to report. FMM has received research grant support from Ansun, Astellas, Cidara, Chimerix, F2G, Gilead, Merck, Shire and WHISCON and has received consulting honoraria from Alexion, Amplyx, Astellas, Basilea, Fate, GlaxoSmithKline, Merck, Pfizer, Roche Molecular diagnostics, Shire and United Medical. SPH has research funding from Merck and AiCuris.

Funding Information:
MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant? Qu?bec.

Publisher Copyright:
© 2019 Blackwell Verlag GmbH

Keywords

Aspergillus
invasive aspergillosis
isavuconazole
posaconazole
voriconazole

Publisher link

10.1111/myc.13013

Find It

Find It at U of M Libraries

Cite this

@article{82fdac40ca744041baec1775b63adb20,

title = "Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis",

abstract = "In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.",

keywords = "Aspergillus, invasive aspergillosis, isavuconazole, posaconazole, voriconazole",

author = "Cheng, {Matthew P.} and Orejas, {Jos{\'e} L.} and Esther Arbona-Haddad and Bold, {Tyler D.} and Solomon, {Isaac H.} and Kaiwen Chen and Alisha Pandit and Kusztos, {Amanda E.} and Cummins, {Kaelyn C.} and Alexis Liakos and Marty, {Francisco M.} and Sophia Koo and Hammond, {Sarah P.}",

note = "Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant{\'e} Qu{\'e}bec. Funding Information: These results were presented in abstract form at IDWeek 2018, Abstract #358. This manuscript was prepared as part of routine work. MPC, JLO, EAH, TDB, IHS, KCC, AP, AEK, KC and SK have no relevant disclosures to report. FMM has received research grant support from Ansun, Astellas, Cidara, Chimerix, F2G, Gilead, Merck, Shire and WHISCON and has received consulting honoraria from Alexion, Amplyx, Astellas, Basilea, Fate, GlaxoSmithKline, Merck, Pfizer, Roche Molecular diagnostics, Shire and United Medical. SPH has research funding from Merck and AiCuris. Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant? Qu?bec. Publisher Copyright: {\textcopyright} 2019 Blackwell Verlag GmbH",

year = "2020",

month = jan,

day = "1",

doi = "10.1111/myc.13013",

language = "English (US)",

volume = "63",

pages = "58--64",

journal = "Mycoses",

issn = "0933-7407",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Use of triazoles for the treatment of invasive aspergillosis

T2 - A three-year cohort analysis

AU - Cheng, Matthew P.

AU - Orejas, José L.

AU - Arbona-Haddad, Esther

AU - Bold, Tyler D.

AU - Solomon, Isaac H.

AU - Chen, Kaiwen

AU - Pandit, Alisha

AU - Kusztos, Amanda E.

AU - Cummins, Kaelyn C.

AU - Liakos, Alexis

AU - Marty, Francisco M.

AU - Koo, Sophia

AU - Hammond, Sarah P.

N1 - Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Santé Québec. Funding Information: These results were presented in abstract form at IDWeek 2018, Abstract #358. This manuscript was prepared as part of routine work. MPC, JLO, EAH, TDB, IHS, KCC, AP, AEK, KC and SK have no relevant disclosures to report. FMM has received research grant support from Ansun, Astellas, Cidara, Chimerix, F2G, Gilead, Merck, Shire and WHISCON and has received consulting honoraria from Alexion, Amplyx, Astellas, Basilea, Fate, GlaxoSmithKline, Merck, Pfizer, Roche Molecular diagnostics, Shire and United Medical. SPH has research funding from Merck and AiCuris. Funding Information: MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Sant? Qu?bec. Publisher Copyright: © 2019 Blackwell Verlag GmbH

PY - 2020/1/1

Y1 - 2020/1/1

N2 - In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

AB - In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

KW - Aspergillus

KW - invasive aspergillosis

KW - isavuconazole

KW - posaconazole

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=85074848693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074848693&partnerID=8YFLogxK

U2 - 10.1111/myc.13013

DO - 10.1111/myc.13013

M3 - Article

C2 - 31587405

AN - SCOPUS:85074848693

SN - 0933-7407

VL - 63

SP - 58

EP - 64

JO - Mycoses

JF - Mycoses

IS - 1

ER -

Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this